In the 22 years between March 1979 and February 2001, we treated 16 patients--10 men and 6 women aged 10-80 years (mean: 44 years)--with mucoepidermoid carcinoma (MEC) of the salivary gland, evaluating them clinically and histopathologically. Tumor sites included 12 at the parotid gland, 3 at the submandibular gland, and 1 at the minor salivary gland. All tumors were graded histopathologically based on the criteria of Goode et al. as follows: low grade (n = 10), intermediate grade (n = 1), and high grade (n = 5). Female gender was associated with low grade MEC and male gender with high grade MEC (P < 0.05). The age at onset in high grade MEC was older than that in low grade MEC (P < 0.005). Lymph-node metastasis was detected in 7 out of the 16 patients (44%) associated significantly with high grade MEC (P < 0.05). Distant metastasis was detected in 4 of 16 patients (25%). Distant metastasis was significantly associated with high grade MEC (P < 0.05). Local recurrence was detected in 3 of 15 patients undergoing surgery (20%). No difference was seen in local recurrence frequency between low and high grade MEC. Survival was calculated with Kaplan-Meier's method. In all 16, 5-year survival was 86% and 10-year survival 75%. Five-year survival in low grade MEC was 100%, whereas that in high grade MEC was 67% (P < 0.05). In MEC of the salivary gland, it was suggested that the histopathological MEC grade evaluated by Goode's criteria significantly correlated with gender, age, lymph-node metastasis, distant metastasis, and 5-year survival.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3950/jibiinkoka.106.192 | DOI Listing |
Eur J Nucl Med Mol Imaging
January 2025
Department of Radiology & Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands.
Purpose: To report real-world clinical experience with [Lu]Lu-PSMA-I&T targeted radionuclide therapy (TRT) in patients with metastatic castration-resistant prostate cancer (mCRPC) in a single tertiary referral university hospital.
Methods: Patients with mCRPC who were treated with [Lu]Lu-PSMA-I&T TRT as standard of care between February 2022 and August 2023 were included in this retrospective study. Patients were treated with a maximum of six cycles with a fixed activity of 7.
Oral Dis
December 2024
Center of Excellence and Innovation for Oral Health and Healthy Longevity, Faculty of Dentistry, Chulalongkorn University, Bangkok, Thailand.
Objectives: To define tumor immunoarchitectural patterns (IPs) and characterize the immune profile in salivary gland mucoepidermoid carcinoma (MEC) toward assessing MEC prognostic significance and implications for immunotherapy.
Methods: This study analyzed 41 MEC cases, evaluating the tumor IPs and tumor-infiltrating lymphocyte (TIL) parameters by using whole-slide imaging and AI-assisted assessment. Immunohistochemistry of CD3 and CD8 markers was performed to assess key lymphocyte subpopulations.
Skeletal Radiol
December 2024
Department of Rheumatology, Erasmus Medical Centre, Rotterdam, The Netherlands.
Objective: MRI of the hands is valuable for risk-stratification in patients with arthralgia at-risk for developing rheumatoid arthritis (RA). Contrast-enhanced MRI is considered standard for assessment of RA, but has practical disadvantages. It also shows inflammation-like features in the general population, especially at older age, which should be considered in image interpretation.
View Article and Find Full Text PDFCureus
November 2024
Department of Pathology, All India Institute of Medical Sciences, Bhubaneswar, Bhubaneswar, IND.
Mucoepidermoid carcinoma (MEC) is the most common malignant tumor of salivary glands.It usually occurs in major salivary glands. The occurrence of intraosseous MEC (IMEC) is rare and is usually seen in the mandibular premolar and molar regions.
View Article and Find Full Text PDFAJNR Am J Neuroradiol
November 2024
From the Department of Neuroradiology / Head and Neck Imaging (S.A.D., K.O.L., R.D., A.M.K.), Department of Head and Neck Surgery (J.R.W., X.Z., A.M., M.E.Z.), Department of Pathology (S.M.H.), and Department of Endocrine Neoplasia and Hormonal Disorders (M.E.C., N.L.B., R.D., P.I.), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Background And Purpose: Neoadjuvant BRAF-directed therapy and immunotherapy followed by surgery improves survival in patients with BRAF-mutant anaplastic thyroid carcinoma (ATC), more so in those who have complete ATC pathologic response. This study assesses the ability of FDG-PET to non-invasively detect residual high-risk pathologies including ATC and poorly differentiated thyroid carcinoma (PDTC) in the preoperative setting.
Materials And Methods: This retrospective, single-center study included consecutive BRAF-mutant ATC patients treated with at least 30 days of neoadjuvant BRAF-directed therapy and who underwent FDG-PET/CT within 30 days prior to surgery.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!